penetrated the wall of the colon/rectum, MAC30 mRNA expression notably increased in tumors with T3+T4 stage compared to tumors with T1+T2 stage (0.571 8 0.364 vs. 0.404 8 0.115, p = 0.014). MAC30 protein expression in CRCs was also remarkably elevated compared to the adjacent noncancerous mucosa. There was no mutation in the coding region of the MAC30 gene either in CRC or in the noncancerous mucosa. mRNA expression of p53 was notably decreased in HCT-116 p53-/-compared to HCT-116 p53+/+ , while MAC30 did not vary greatly. Conclusion: The overexpression of MAC30 might be involved in the development and aggressiveness of CRCs, especially in the colon.
Significance of mRNA and Protein Expression of MAC30 in Progression of Colorectal Cancer
2) is such a recently identified protein, having a small segment of similarity to an apical gut membrane polyprotein of Haemonchus contortus , to olfactory receptor 30 of Mus musculus , and to cytochrome b in several organisms. MAC30 was first described to be overexpressed in meningiomas, and altered expression was also found in different types of human tumors [3] [4] [5] . MAC30 is expressed at moderate levels in normal pancreatic acinar cells, strongly present in tubular complexes of chronic pancreatitis and observed at low levels in most pancreatic cancer cells. The loss or reduction of MAC30 expression in pancreatic cancer suggests that this gene acts as a tumor suppressor in pancreatic cancer [4] . In contrast to pancreatic cancer, the expression of MAC30 was stronger in breast, stomach and colon cancers compared with the corresponding normal tissues [5] [6] [7] , indicating the importance of MAC30 expression in different types of malignancies.
Not long ago, our research group found that in CRC MAC30 protein expression increased from distant normal mucosa to the primary tumor and to metastasis in the lymph nodes, and was positively related to the expression of proliferating cell nuclear antigen, p53, nucleoporin 88 (Nup88) and, particularly interesting, new cysteine-histidin-rich protein (PINCH) [6] . Strong expression of MAC30 was related to a poor prognosis in CRC patients [6, 7] , indicating that MAC30 protein plays a great role in the development, invasion and metastasis of CRCs. Our question is whether MAC30 mRNA transcription is changed and whether it is related to the clinicopathological variables in CRC.
Patients and Methods

Patients and Specimens
This study was approved by the Ethics Committee of Tangshan Worker's Hospital of Hebei Medical University. Fresh colorectal adenocarcinoma specimens and their adjacent noncancerous tissue were obtained at the time of surgery from 55 cases of colorectal adenocarcinoma and immediately snap-frozen in liquid nitrogen. All patients were diagnosed and treated at the Tangshan Gongren Hospital (Tangshan, China) between January 2007 and December 2008. The fresh normal mucosa samples were collected at the same time. All patients provided informed consent and none of the patients received preoperative radiotherapy or chemotherapy. The patients' gender, age, tumor location, histological type, grade of differentiation, invasive depth and lymph node metastasis were obtained from surgical and pathological records. The mean age of the patients was 57.6 years (range 31-90), of which 64% were male and 36% female. Tumors were located in the colon (n = 26) or the rectum (n = 27), whereas in 2 cases the information was missing; nonmucinous adenocarcinomas (n = 36), mucinous/signet-ring cell carcinomas (n = 17) and 2 were lost; tumors were graded as better (well + moderate, n = 43), worse (poor, n = 9) differentiation and another 3 cases were unknown. All samples were examined by two pathologists (Z.-Y.Z. and Y.-M.H.).
Cell Culture
Human colon carcinoma cell lines, HCT-116 (a kind gift from Dr. B Vogelstein) with wild-type p53 (HCT-116 p53+/+ ) and truncated p53 missing 40 amino acid residues (HCT-116 p53-/-) [8] , were cultivated in McCoy's 5A medium (Sigma-Aldrich, St. Louis, Mo., USA) supplemented with 10% FBS (GIBCO, Invitrogen, Carlsbad, Calif., USA), 1.5 m M L -glutamine (GIBCO) and 1 ! PEST (GIBCO) at 37 ° C in a 5% CO 2 incubator.
cDNA Synthesis and RT-PCR
The tissue specimens were homogenized with a glass homogenizer. Total RNA was extracted from cell pellets and tissue samples using Trizol reagent (Invitrogen, Carlsbad, Calif., USA). Reverse transcription reaction was performed using 2 g of total RNA with Reverse Transcription System (Promega, San Luis Obispo, Calif., USA). The mRNA expression levels of the MAC30 were determined by conventional RT-PCR with GoTaq polymerase (Promega). Primer sequences of MAC30 and ␤ -actin were as followed. MAC30-F: 5 -ACTGCTCAGAACCCACGTCT-3 ; MAC30-R: 5 -ATCATGCCACTGCCCTTTAC-3 ; ␤ -actin-F: 5 -GGAAATCGTGCGTGACATTA-3 ; ␤ -actin-R: 5 -GGAGCAAT-GATCTTGATCTTC-3 . To quantify the expression levels of the target gene, 10 l PCR products were separated by 1.5% agarose gel electrophoresis and quantified by Gel Imaging System after ethidium bromide (10 mg/l) staining. The mRNA expression level of the target gene was defined by the densitometry ratio of the target gene to ␤ -actin.
Quantitative Real-Time RT-PCR
The mRNA expression levels of MAC30 and p53 were examined by quantitative real-time PCR using the SYBR Green Master Mix Kit and the ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, Calif., USA). Primers used for real-time RT-PCR were: MAC30-F: 5 -CCCAGCCTGGTTTAAGTCCTT-3 , MAC30-R: 5 -CCACTTGCAGCTTCCTTTGAG-3 ; p53-F: 5 -TCAACAA -G A T GTTTTGCCAACTG-3 ; p53-R: 5 -ATGTGCT GTGACTG -C T T G T AGATG-3 . Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control of RNA integrity.
Protein Preparation and Western Blot
HCT-116 cells were firstly used to validate the MAC30 antibody. When the cells grew up to 10 6 , they were collected, washed in PBS and lysed in RIPA buffer along with the frozen colorectal tissues, containing 150 m M NaCl, 1% Triton X-100, 0.1% SDS, 50 m M Tris (pH 8.0) and a Complete TM Mini Protease Inhibitor Cocktail Tablet (Roche, Basel, Switzerland). Protein concentration was determined with the colorimetric BCA protein assay reagent (Pierce, Woburn, Mass., USA). Samples containing 50 g of total protein were boiled for 5 min in the presence of 2-mercaptoethanol and dithiothreitol. Solubilized proteins were separated by electrophoresis in 10% SDS polyacrylamide gels and transferred to the polyvinylidene fluoride membranes (Millipore Corporation, Billerica, Mass., USA) by electroblotting in 25 m M Tris, 192 m M glycine and 20% methanol (pH 8.3). The polyvinylidene fluoride membranes were washed with TBS-Tween 20 for 5 min with five changes and blocked with blocking buffer (5% nonfat dry milk solution) and incubated for 2 h on an orbital shaker at room temperature. Then, the membranes were incubated with a monoclonal antibody MAC30 1-19 [3] , diluted 1: 5 in 5% nonfat milk/ TBS-Tween 20 overnight at 4 ° C. The membranes were rinsed with TBS-Tween 20 and incubated with peroxidase-conjugated goat anti-mouse immunoglobulins (1: 5,000; Zhongshan Gold Bridge Biotechnology, Beijing, China) in 5% nonfat milk for 2 h on an orbital shaker at room temperature. The membranes were washed with TBS-Tween 20 between each incubation step, for 5 min with five changes on an orbital shaker at room temperature. At last, the membranes were stained by DAB. MAC30 protein migrates in sodium dodecyl polyacrylamide gel as a 24-kDa monomer, reaction of the MAC30 antibody with the protein resulted in the bands, which could be detected against the standard marker used.
Nucleotide Sequence Analysis
The MAC30 gene coding region sequence (CDS) was analyzed by extracting genomic DNA from the fresh CRC and noncancerous colon tissues with a tissueGen DNA kit (CWBIO, Beijing, China) according to its manufacturer's instructions. CDS of the MAC30 gene (gene ID: 27346, nt 146-271; 6409-6553; 7440-7699) was directly PCR-amplified in a thermal cycler. The sequences of primers used for MAC30 analysis are listed in table 1 . PCR conditions were as follows: 1 cycle at 95 ° C for 4 min, 35 cycles at 95 ° C for 40 s, respective annealing temperature for 40 s, and at 72 ° C for 40 s, followed by 1 cycle at 72 ° C for 10 min. After confirmation by agarose electrophoresis and ethidium bromide staining, the PCR products were purified and automatically sequenced with an ABI PRISM 3730 (Applied Biosystems), then analyzed with Chromas software version 2.0 (Gene Codes Corporation, Ann Arbor, Mich., USA). All sequencing reactions were performed in both forward and reverse directions, by independent PCR.
Statistical Analysis
Statistical analysis was performed using the SPSS software (version13.0; SPSS, Chicago, Ill., USA). Relative levels of MAC30 mRNA expression (MAC30/ ␤ -actin) were expressed as means 8 standard deviation. The difference of MAC30 mRNA expression among CRC, adjacent noncancerous mucosa samples and distant mucosa was tested by one-way ANOVA. Associations between MAC30 mRNA expression and clinical parameters were analyzed by Student's t test or ANOVA. Differences with p ! 0.05 were considered to be statistically significant. Figure 1 shows the difference of MAC30 mRNA expression in CRC, the matched adjacent noncancerous mucosa and distant normal mucosa. MAC30 mRNA ex- RT-PCR products of MAC30 were detected by electrophoresis. ␤ -Actin, as the standard, was also examined. Marker = 100-to 600-bp ladder; 1 = colorectal tumor; 2 = adjacent noncancerous mucosa; 3 = proximate normal mucosa; 4 = distant normal mucosa. MAC30 mRNA expression level was defined by the densitometry ratio to ␤ -actin. On the histogram, MAC30 mRNA expression in CRC was notably increased compared to the other three groups. * p ! 0.01. pression in CRC was notably increased compared to that in the adjacent and distant normal mucosa (CRC vs. adjacent non-cancerous mucosa, CRC vs. distant normal mucosa; both p ! 0.01).
Results
mRNA Expression of MAC30 in CRC, Adjacent and Distant Normal Mucosa
To further verify the above results, quantitative realtime RT-PCR was performed in 18 CRC samples, and MAC30 mRNA expression in CRC was greatly elevated compared with the adjacent noncancerous mucosa and distant normal mucosa, which was consistent with the conventional RT-PCR results ( fig. 2 ) . 
Relationship between MAC30 mRNA Expression and Clinicopathological Characteristics
Assessment of MAC30 and p53 in HCT-116 Cells
We examined the expression of MAC30 and p53 in HCT-116 wild-type (HCT-116 while MAC30 mRNA expression was found to be unchanged ( fig. 3 b) .
Western Blot Analysis
Lysates from HCT-116 cells were performed by SDS-PAGE to validate the MAC30 antibody. As shown in figure 4 a, a band was seen at approximately 24 kDa , which was consistent with the description of the MAC30 antibody. We further examined MAC30 protein expression in CRC and adjacent noncancerous mucosa to understand the difference by Western blot. The bands seen in human colon tissue ( fig. 4 b) were the same as those found in HCT-116 cells ( fig. 4 a) , which indicated that these bands represent authentic MAC30, not cross-reacting protein. The expression of MAC30 protein in CRC was stronger than that in the adjacent noncancerous mucosa ( fig. 4 c) .
DNA Sequencing Results
We sequenced all coding nucleotides (528 bp, nt 146-271; 6,409-6,553; 7,440-7,699) that are distributed to three exons and regrettably there was no difference between the tumor and the matched noncancerous mucosa. All nucleotides were the same with the original sequence (PubMed, gene ID 27346) and there were no mutations either in the tumor or the noncancerous mucosa ( fig. 5 ). 
Discussion
In the present study, we observed that MAC30 mRNA expression in CRC was significantly increased compared to the matched distant or adjacent noncancerous mucosa. Up to now, only one study reported MAC30 mRNA overexpressed in 40 colon cancers and 27 normal tissue samples. However, the samples did not match in that study, an increased level of MAC30 mRNA in primary tumors was shown compared to the normal samples [5] . And an increased level of MAC30 mRNA was shown in breast cancers compared to normal breast tissue, but there was significantly decreased MAC30 in pancreatic and renal cancers [5] . Shortly after, Wilcox et al. [9] found the expression of TMEM97, encoding MAC30 protein, was suppressed 2.4-fold in the ovarian cancer samples relative to normal ovarian surface epithelial cells. Our present data of MAC30 mRNA expression significantly increased in the tumor compared with the normal mucosa was in line with our previous immunostaining results observed in CRCs, where MAC30 expression was increased from distant normal mucosa to CRC [6] . The results of Western blot performed in the present study also confirmed that the expression of MAC30 protein in CRC was notably upregulated compared to that in the adjacent noncancerous mucosa. Taken together, either mRNA or protein of MAC30 expression was increased in CRC compared to normal colorectal mucosa, indicating that MAC30 may function as an oncogene and play an important role in the development of CRC.
In the present study, we also analyzed the relationship of the MAC30 mRNA with clinicopathological variables and found that overexpression of MAC30 mRNA was closely associated with the infiltrate depth and tumor lo- Color version available online cation, both being the factors that were related to the prognosis of the patients with CRC [10] . With the increase in depth of invasion, MAC30 mRNA expression notably elevated. When the tumor invaded the serosal layer, the level was much higher compared to those in the mucous and muscular layers. Our previous studies reported that overexpression of MAC30 protein in the cytoplasm of oral squamous cell carcinoma may predict nodal metastasis and poor differentiation [11] , and that the strong expression of MAC30 protein in the metastasis of the lymph node was related to an unfavorable outcome of CRC patients [6] . Therefore, we can see that MAC30, not only its protein but also mRNA, may be biomarkers to be implicated in the development and prognosis of CRC.
Tumor location was another factor that was closely associated with the progression of CRC in relation to biological features. The current study showed that MAC30 mRNA expression in colon cancers was significantly higher than in rectal cancer. Several studies have suggested that patients with colon cancer had a better prognosis than those with rectal cancer [12] . And one study has reported that the orotate phosphoribosyltransferase level was significantly higher in colon tumors than in rectal tumors [13] . However, tumors in distal colon cancer and left-sided colon tumor location were significantly correlated with poor overall survival [14] , which might be related to the chromosome instability, for example, K-ras mutation, p53 and APC/ ␤ -catenin. Here we have shown a new factor, MAC30, which may also be involved in cancer development in the different sites.
In the present study, MAC30 mRNA expression in mucinous/signet-ring cell carcinomas had a trend of increase, compared with nonmucinous carcinomas. In our previous study, we found that MAC30 was positively related to PINCH, Nup88 and p53 expression [6] . PINCH is the protein involved in stromal-related tumor development and aggressiveness [15, 16] , and the frequency of PINCH strong expression in mucinous and signet-ring cell carcinomas was higher compared to nonmucinous carcinomas [17] . More interestingly, strong immunostaining stroma for PINCH at the invasive margin is an independent prognostic indicator in CRC patients [18] . MAC30 mRNA was positively related to PINCH and Nup88 mRNA (data not shown), which was in line with the protein. MAC30 acts as a primary transcriptional target of p53 and could be downregulated by p53 [19] . We could speculate that the high expression of MAC30 in CRC might correlate with p53 mutation. Therefore, we examined the expression of p53 and MAC30, in two colon cancer cell lines, p53-/-and HCT-116 p53+/+ , the results showed that mRNA expression of p53 was notably decreased in p53-/-than in HCT-116 p53+/+ , while MAC30 was not greatly varied, which was similar to the findings of FXYD3 [20] , where FXYD3 expression is dramatically increased after f luoropyrimidine 5-fluorouracil exposure only in the cell line with a functional p53, while FXYD3 expression is unchanged in a p53-null cell line. Our previous study found FXYD3 was highly expressed in the primary tumor compared to adjacent normal mucosa and tended to be positively related to the expression of p53 [21] . Hanski et al. [22] found that the mutation frequency of p53 was significantly different in colorectal mucinous and non-mucinous adenocarcinomas. Interaction and mechanism of MAC30 and p53 in CRC need to be further investigated.
We have sequenced all coding nucleotides (528 bp) of the MAC30 gene and did not find any mutation. However, we could not propose that the difference of MAC30 mRNA and protein in CRC from normal mucosa resulted from some mutations, since we only examined one paired case, so it is necessary to examine more cases to validate the result. Nevertheless, we might presume that there are some changes in the introns of the gene or even methylation, leading to MAC30 overexpression in CRC. A study showed an intronic single nucleotide polymorphism (IVS1 + 12 C 1 T) in one case of 39 ovarian cancer samples [9] .
Conclusion
In the present study, the expression of MAC30 was remarkably elevated in CRC compared to the adjacent noncancerous and distant normal mucosa. The overexpression of MAC30 might be involved in the development and aggressiveness of CRCs, especially in the colon.
